REG - Ondine Biomedical - Notice of AGM

Ondine BiomedicalAnnouncement

04/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250604:nRSD2503La&default-theme=true

RNS Number : 2503L  Ondine Biomedical Inc.  04 June 2025

4 June 2025

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

Notice of AGM

 

Ondine Biomedical Inc. (AIM: OBI) announces that the notice of the Company's
2025 Annual General Meeting ("AGM") and the associated form of proxy have been
published today on the Company's website
at https://ondinebio.com/investors/reports-documentation/
(https://ondinebio.com/investors/reports-documentation/) .

 

Printed copies of the notice of AGM and form of proxy will be posted today to
registered shareholders who have elected to receive paper communications.

 

The Company's AGM will be held virtually at 16:00 BST (08:00 Pacific time) on
26 June 2025. Details of how to access the meeting are contained in the notice
of AGM.

 

All shareholders are encouraged to submit their vote by proxy, well in advance
of the meeting. Details of how to vote by proxy are contained in the notice of
AGM. All valid proxy votes (whether submitted electronically or in hard copy
form) will be included in the poll vote to be taken at the meeting.

 

The items of business to be voted on at the Meeting are:

·    the re-election of Carolyn Cross, Nicolas G. Loebel, Jean Charest,
Jean Duvall, Junaid Bajwa, and Margaret Shaw as directors of the Company to
hold office until the 2026 annual meeting of shareholders or until their
successors are elected and qualified, subject to earlier resignation or
removal;

·    the re-appointment of PricewaterhouseCoopers LLP, Chartered
Professional Accountants, as auditors for the Company for the ensuing year;
and

·    to transact such other business as may properly come before the
Meeting.

 

The result of the AGM will be announced after its conclusion and published on
the Company's website.

 

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 RBC Capital Markets (Broker)
 Kathryn Deegan                                              +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                            +44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFJMBTMTJMBFA